US National Institutes of Health
J&J’s Erleada prostate cancer study shows significant reduction in risk of metastasis
Erleada plus hormone therapy significantly improved key short- and long-term clinical outcomes
Pfizer and Innovent Biologics agree on deal worth up to $10.5bn
The companies plan to research and develop 12 new cancer treatments
One-carbon Therapeutics collaborates with Tempus in cancer treatment
The treatment is currently being evaluated in a phase 1/2 multicentre clinical study
Gilead to acquire Tubulis for up to $5bn
The acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need
Vibrant Therapeutics raises $61m in funding to advance intelligent therapeutics pipeline
The financing includes new investors Pfizer Ventures and Apricot Capital, bringing the total capital raised to $100m
AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer
Around one in five breast cancer cases are HER2-positive
Medicus Pharma completes patient enrolment for basal cell carcinoma trial
Interim results have shown over 60% clinical clearance in patients treated with SkinJect
Researchers at University of Geneva develop test platform for cancer treatments
The new platform could speed up testing while reducing the need for animal models
Major prostate cancer screening trial launched in UK
The £42m Transform trial will recruit men aged 50-74, with a lower age limit of 45 for some men
Merck and Blackstone agree on funding for cancer protein antibody
The funding will support late-stage clinical development of the investigational antibody-drug conjugate
Ipsen to acquire ImCheck Therapeutics in a deal worth up to €1bn
The acquisition includes a clinical stage acute myeloid leukaemia treatment currently in phase 1/2 trials
Eli Lilly’s Inluriyo approved by FDA for breast cancer
The oral drug can be used to treat advanced or metastatic breast cancer